Short interest for Q32 Bio gives investors a sense of the degree to which investors are betting on the decline of Q32 Bio's stock. Short interest data is updated every two weeks.

Q32 Bio (NASDAQ:QTTB) Stock, Short Interest Report

Q32 Bio

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LGVN

LOCL

MNDR

MRNS

NMRA

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RARE

RENT

SNGX

SNPO

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Q32 Bio Inc

WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) has outperformed the market over the past 15 years by 30.84% on an annualized basis producing an average annual return of 43.72%. Currently, WEX has a market capitalization of $7.44 billion. 
Buying $100 In WEX: If an investor had bought $100 of WEX stock 15 years ago, it would be worth $23,055.84 today based on a price of $177.53 for WEX at the time of writing.
<h3>WEX's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720215026_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $23,000 Today

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 10 years by 3.57% on an annualized basis producing an average annual return of 14.51%. Currently, Blackstone has a market capitalization of $92.14 billion. 
Buying $100 In BX: If an investor had bought $100 of BX stock 10 years ago, it would be worth $380.79 today based on a price of $122.60 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720215021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Blackstone Stock In The Last 10 Years

Calls for President Joe Biden <a href="https://www.benzinga.com/news/24/06/39540588/joe-bidens-debate-performance-triggers-democratic-panic-biden-sounds-hoarse-looks-tired-and-is-babbl">to step down</a> ahead of <a href="https://www.benzinga.com/topic/2024-electionhttps://www.benzinga.com/topic/2024-election">the 2024 election</a> and make way for another candidate, such as Vice President Kamala Harris, have grown. Yet, Biden remains vocally committed to the <a href="https://www.benzinga.com/news/24/07/39628794/biden-vs-trump-new-poll-shows-president-still-very-much-in-race-despite-debate-fiasco-but-final-outc">presidential race as of Friday</a>.
Meanwhile, the latest Morning Consult poll, conducted after the first presidential debate, saw Ex-President and presumptive GOP nominee Donald Trump retake his lead.
What Happened: The new <a href="https://pro.morningconsult.com/trackers/2024-presidential-election-polling">poll </a>of nationally registered voters shows the following results, with the results from <a href="https://www.benzinga.com/general/politics/24/06/39538536/trump-vs-biden-2024-presidential-candidates-tied-ahead-of-first-debate-abortion-hits-high-for-be">the June 25 poll</a> in parentheses:
<ul>
<li>Joe Biden: 43% (44%)</li>
<li>Donald Trump: 44% (44%)</li>
<li>Someone Else: 8% (8%)</li>
<li>Don't Know: 5% (4%)</li>
</ul>
Of the Democratic voters polled, 87% have Biden as their top pick. That&#8217;s in line with the previous poll. Eighty-nine percent of Republican voters polled have Trump as their top pick, which is in line with the previous poll.
Independent voters, who could decide the election, selected their 2024 pick as follows, with the June 25 results in parentheses:
<ul>
<li>Joe Biden: 33% (34%)</li>
<li>Donald Trump: 37% (37%)</li>
<li>Someone Else: 18% (18%)</li>
<li>Don't Know: 12% (11%)</li>
</ul>
Read Also:<a href="https://www.benzinga.com/general/politics/24/06/39558557/kamala-harris-defends-bidens-slow-start-at-debate-with-strong-finish-clinton-newsom-obama-race-t"> Kamala Harris Defends Biden&#8217;s &#8216;Slow Start&#8217; At Debate With &#8216;Strong Finish&#8217;: Clinton, Newsom, Obama Race To Support President</a>
Why It's Important: After <a href="https://www.benzinga.com/general/politics/24/07/39620336/biden-contemplates-future-in-2024-race-after-poor-debate-showing-report">the recent debate performance</a>, Biden could lose support in election polls and the next Morning Consult poll could show a much different result.
While Biden only trails by one percentage point in the latest Morning Consult poll, his campaign won't like several findings.
<ul>
<li>68% of voters say Biden is too old for the presidency, compared to 64% before the debate. </li>
<li>Among Democratic voters, 50% said Biden was too old, up seven percentage points from before the debate.</li>
<li>The poll found that only 35% of voters consider Biden to be in good health, compared to 41% before the presidential debate.</li>
<li>63% of Democratic voters see Biden in good health, compared to 75% before the debate.</li>
<li>When asked if Biden is mentally fit, 37% of voters said yes, compared to 43% before the debate. </li>
<li>Among Democratic voters, 68% said Biden is mentally fit, down from 77% before the debate.</li>
</ul>
Biden being mentally fit hit the lowest score for all voters and Democrats since polling began in 2020.
For a ninth consecutive week, Biden's net favorability rating has been ahead of Trump's, marking Biden's longest streak since April 2023.
However, voters were 31 points more likely of having heard, read or seen something negative than positive about Biden after the debate. This marked Biden's worst buzz rating since tracking for the 2024 election began in November 2022.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/07/39625833/who-gets-the-fundraising-money-if-joe-biden-drops-out-of-2024-election">Who Gets The Fundraising Money If Joe Biden Drops Out Of 2024 Election?</a></li>
</ul>

Politics

Trump Vs. Biden: Former President Retakes Lead In 2024 Election Poll After Debate, More Voters See Incumbent As 'Too Old'

Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) has outperformed the market over the past 5 years by 5.07% on an annualized basis producing an average annual return of 18.36%. Currently, Permian Resources has a market capitalization of $10.40 billion. 
Buying $1000 In PR: If an investor had bought $1000 of PR stock 5 years ago, it would be worth $2,235.38 today based on a price of $16.06 for PR at the time of writing.
<h3>Permian Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720213227_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Permian Resources Stock In The Last 5 Years

Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) has outperformed the market over the past 20 years by 2.25% on an annualized basis producing an average annual return of 10.58%. Currently, Amkor Tech has a market capitalization of $9.86 billion. 
Buying $100 In AMKR: If an investor had bought $100 of AMKR stock 20 years ago, it would be worth $758.71 today based on a price of $40.06 for AMKR at the time of writing.
<h3>Amkor Tech's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720213223_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMKR

Here's How Much $100 Invested In Amkor Tech 20 Years Ago Would Be Worth Today

Dozens of high-power business leaders, including Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) heir Christy Walton, have <a href="https://www.benzinga.com/news/24/07/39641760/biden-vs-trump-incumbent-trails-by-widest-margin-in-this-election-cycle-but-more-than-half-unenthusi">signed a letter </a>to President Joe Biden asking him to give up his re-election bid, while praising his time in the Oval Office.
The letter, which was obtained by Bloomberg and signed by 168 executives and billionaires, credit Biden, 81, with "rescuing our democracy from the deepest threats it has known since the Civil War." 
But the letter, which came from the Leadership Now Project, also encouraged Biden to step aside by telling him, "to ensure that legacy is cemented, we ask that you pass the torch of leadership to the next generation of Democratic leaders by ending your reelection bid," Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-07-05/a-14-billion-walmart-heir-joins-novogratz-urging-biden-to-exit?srnd=homepage-americas&amp;sref=TBDibEcD">reported.</a>
Also Read: <a href="https://drupal-cloudfront.benzinga.com/markets/cryptocurrency/24/07/39601856/anthony-scaramucci-predicts-major-crypto-gains-if-biden-wins-election">Anthony Scaramucci Predicts Major Crypto Gains if Biden Wins Election</a>
Other signatories include Michael Novogratz, CEO of Galaxy Investment Partners,&nbsp;and&nbsp;Paul Tagliabue, former commissioner of the National Football League.
Walton, 75, is worth about $14 billion, according to the Bloomberg Billionaires Index. The philanthropist is the widow of John T. Walton, the second son of Walmart Inc. founder Sam Walton.
 Walton, Novogratz and Tagliabue haven't donated to Biden's re-election campaign, Bloomberg reported.
The letter, which also told Biden that &#8220;nothing short of American democracy is at stake this November,&#8221; has come after Leadership Now <a href="https://www.leadershipnowproject.org/statement-a-new-nominee-to-protect-democracy">published </a>an unsigned statement on Wednesday that said business leaders have &#8220;heard from many individuals who share our deep concerns about the present course but fear speaking out.&#8221;
&#8220;But speaking out is our duty in a democracy and the time to do it is now,&#8221; Leadership Now said in its statement.
&#8220;We call on others to join us in making this urgent call.&#8221;
Leadership Now pointed to Biden&#8217;s performance in his June 27 debate with former President Donald Trump in requesting that the president give up his campaign for a second term.
&#8220;What we witnessed Thursday night in the presidential debate was deeply concerning,&#8221; the organization said.
&#8220;Donald Trump repeatedly lied, preyed on our worst fears and grievances, and refused to commit to accepting the 2024 election results. Unfortunately, President Biden failed to effectively make the case against Trump, and we now fear the risk of a devastating loss in November.&#8221;
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39638541/trumps-unfounded-claims-kamala-harris-stir-controversy-shes-so-bad-shes-so-pathetic">Trump&#8217;s Unfounded Claims About Kamala Harris Stir Controversy: &#8216;She&#8217;s So Bad, She&#8217;s So Pathetic&#8217;</a></li>
</ul>
Photo: Shutterstock

Biden Should Step Aside, Say Business Leaders Including Walmart Heir

June&#8217;s Bureau of Labor Statistics jobs report <a href="https://www.benzinga.com/markets/equities/24/07/39646053/mixed-picture-for-fed-june-payrolls-rise-more-than-expected-unemployment-rate-ticks-up-wage-grow">shows unemployment rising</a>, signaling a continued slowing in the U.S. economy. 
University of Pennsylvania Wharton professor Jeremy Siegel reacted to the data, recommending the Federal Reserve to <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39648975/fed-needs-to-frontload-interest-rate-cuts-say-4-economists-labor-markets-cooling-">cut interest rates</a> in response.
What Happened: Siegel <a href="https://www.cnbc.com/video/2024/07/05/we-are-in-a-slowing-economy-says-whartons-jeremy-siegel.html">appeared</a> on CNBC on Friday afternoon to discuss Friday&#8217;s &#8220;weak report.&#8221;
&#8220;I think it&#8217;s really time for Fed Chairman [Jerome] Powell to tee up in the July meeting a cut in September, and maybe another one in November,&#8221; Siegel said. &#8220;I think inflation is definitely under control and I don&#8217;t want to see this slowing economy turn into something worse.&#8221;
Siegel referenced economist Claudia Sahm&#8216;s <a href="https://www.benzinga.com/news/econ-s/24/07/39649271/us-close-to-recession-warning-as-june-jobs-report-shows-rising-unemployment">leading &#8220;Sahm Rule&#8221;</a> as a means to predicting recessions. The threshold is met when the three-month moving average of the&nbsp;unemployment rate rises by 0.5% or more relative to the minimum of the three-month averages from the previous 12 months. 
June&#8217;s figure is very close to approaching the 0.50%. A recession still should not be considered likely, Siegel says, especially if a September rate cut by the Federal Reserve would forestall a recession.
&#8220;Why not be preemptive? The commodity market is under control, all the others are under control. We&#8217;ve talked so long about the fact that if they used realistic shelter costs in their CPI, they [inflation indicators] would be much lower than what they have now. I think he [Powell] can afford to bring us a more normal Fed Funds Rate in relationship to those long rates&#8230;&#8221;
Why it Matters: The market is currently predicting a 77% chance for a September interest rate cut with additional cuts possible in November, <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">according</a> to the CME Group. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39650506/magnificent-7-stocks-propel-s-p-500-nasdaq-100-to-record-highs-as-jobs-data-fuels-rate-cut-bets-">Magnificent 7 Stocks Propel S&amp;P 500, Nasdaq 100 To Record Highs As Jobs Data Fuels Rate Cut Bets; Gold Miners Rally: What&#8217;s Driving Markets Friday?</a></li>
</ul>

Economics

Wharton's Jeremy Siegel Implores Jerome Powell To Signal September Rate Cuts: 'We Are In A Slowing Economy'

Grown Rogue International Inc.(CSE:<a class="ticker" href="https://www.benzinga.com/stock/GRIN#CSE">GRIN</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRUSF#OTC">GRUSF</a>) has entered a secured drawdown promissory note agreement with ABCO Garden State, LLC, a New Jersey licensed cultivator. As of Friday, July 5th, Grown Rogue owns 44% of ABCO, with an option to acquire an additional 26% of ABCO, subject to regulatory approval.
On May, 31, Grown Rogue, obtained licensing approval with the New Jersey Cannabis Regulatory Commission (CRC) and <a href="https://www.benzinga.com/markets/cannabis/24/06/39188107/craft-cannabis-co-grown-rogue-expands-in-this-booming-east-cost-weed-market-via-new-acquisition" target="_blank" rel="noreferrer noopener">closed its first option to acquire 44% of ABCO</a>.
&#8220;As we reach the final stages of Phase I construction, this additional capital will be used to finish construction and provide the necessary working capital to become operational," stated Obie Strickler, CEO of Grown Rogue. "Our Phase I work has included many of the necessary improvements required to accelerate Phase II completion such as full panel installation, the purchase of on-site HVAC equipment, and the fulfillment of fire safety requirements.&#8221;
The news comes on the heels of the company reorganizing shares to keep<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/06/39489016/craft-weed-company-grown-rogue-reorganizes-shares-to-keep-its-foreign-private-issuer-status-in-t" rel="noreferrer noopener"> its foreign private issuer status in the US</a>.
Read Also: <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/05/39088512/grown-rogue-reports-record-q1-revenue-ceo-calls-these-two-states-primary-growth-drivers" rel="noreferrer noopener">Grown Rogue Reports Record Q1 Revenue, CEO Calls These Two States &#8216;Primary Growth Drivers&#8217;</a>
<h2 class="wp-block-heading">Key Takeaways</h2>
<ul>
<li>Grown Rogue will lend up to $3,000,000 to ABCO under the note agreement to support ongoing construction and working capital as ABCO ramps up its operations. On June 25, 2024, Grown Rogue advanced $500,000 to ABCO, representing the first drawdown.</li>
<li>The note has preferential repayment, and interest on the outstanding principal will accrue at 10.5% per annum.</li>
<li>The note, including all accrued and unpaid interest, shall be due and payable on June 25, 2025.</li>
</ul>
&#8220;Phase I remains substantially on schedule and on budget, with final occupancy approvals expected later this month and sales anticipated to commence in the fourth quarter," Strickler continued. "Phase II construction is expected to be completed in the first quarter of 2025, with sales anticipated to commence in the second quarter of 2025. With both Phases complete and a total flowering canopy of ~16,000 square feet, we expect to be producing in excess of 1,000 pounds of whole flower per month in New Jersey.&#8221;
New Jersey's Attractive Potential
According to the New Jersey Cannabis Regulatory Commission, the state reported over $800 million in cannabis sales in 2023, growing more than 44% year-over-year. The fourth quarter sales reached a record with $220 million in sales, growing 7% sequentially. Furthermore, the state's recreational cannabis revenue topped $201 million in early 2024, a substantial rise from the previous year. This boost comes as the number of dispensaries jumped from 24 to 130 within a year, putting New Jersey on track to <a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/06/39271024/new-jerseys-cannabis-market-excels-as-new-york-continues-to-face-setbacks" rel="noreferrer noopener">becoming a billion-dollar market</a>.
<h2 class="wp-block-heading">Price Action</h2>
Grown Rogue shares traded 48.87% lower at 65 cents per share at the time of writing Monday after the close.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39193860/the-green-garden-state-all-you-need-to-know-about-new-jerseys-cannabis-market" target="_blank" rel="noreferrer noopener">The Green Garden State: All You Need To Know About New Jersey&#8217;s Cannabis Market</a></li>
</ul>
To keep on top of what is happening with cannabis stocks and everything across the industry, join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices go up by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.
Photo: Courtesy of Kyrylo Vasyliev via Shutterstock

Cannabis

CSE:GRIN

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

GRUSF

Craft Weed Company Bets On New Jersey Market, Now Owns 44% Of This State-Licensed Cultivator

Financial giants have made a conspicuous bearish move on Mastercard. Our analysis of options history for Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) revealed 11 unusual trades.
Delving into the details, we found 36% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $168,886, and 6 were calls, valued at $664,821.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $320.0 to $540.0 for Mastercard during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Mastercard's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Mastercard's whale activity within a strike price range from $320.0 to $540.0 in the last 30 days. 
<h3>Mastercard Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720212594_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$45.95</td>
<td>$43.0</td>
<td>$44.5</td>
<td>$480.00</td>
<td>$293.7K</td>
<td>970</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.35</td>
<td>$10.55</td>
<td>$10.55</td>
<td>$540.00</td>
<td>$168.8K</td>
<td>149</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.25</td>
<td>$8.1</td>
<td>$8.25</td>
<td>$500.00</td>
<td>$59.4K</td>
<td>2.4K</td>
<td style="text-align: right;">21</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$34.6</td>
<td>$34.25</td>
<td>$34.55</td>
<td>$440.00</td>
<td>$51.8K</td>
<td>67</td>
<td style="text-align: right;">16</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$34.45</td>
<td>$33.15</td>
<td>$33.8</td>
<td>$440.00</td>
<td>$50.6K</td>
<td>67</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>

<h3>About Mastercard</h3>
Mastercard is the second-largest payment processor in the world, having processed close to over $9 trillion in volume during 2023. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
After a thorough review of the options trading surrounding Mastercard, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Mastercard</h3>
<ul>
<li>With a trading volume of 2,219,374, the price of MA is down by -0.47%, reaching $446.07.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 20 days from now.</li>
</ul>
<h3>Expert Opinions on Mastercard</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $525.0.
<ul>
<li>An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Mastercard, which currently sits at a price target of $525. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Mastercard, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on Mastercard: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with COP, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for ConocoPhillips.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 12%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $58,000, and 6 are calls, for a total amount of $403,009.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $115.0 for ConocoPhillips over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of ConocoPhillips stands at 2488.4, with a total volume reaching 1,746.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ConocoPhillips, situated within the strike price corridor from $100.0 to $115.0, throughout the last 30 days.
<h3>ConocoPhillips Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720212589_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$1.01</td>
<td>$1.0</td>
<td>$1.01</td>
<td>$115.00</td>
<td>$101.0K</td>
<td>6.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$27.95</td>
<td>$23.55</td>
<td>$27.01</td>
<td>$100.00</td>
<td>$81.0K</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$1.09</td>
<td>$0.96</td>
<td>$1.02</td>
<td>$115.00</td>
<td>$72.9K</td>
<td>6.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/02/24</td>
<td>$2.92</td>
<td>$2.89</td>
<td>$2.9</td>
<td>$113.00</td>
<td>$64.9K</td>
<td>28</td>
<td>2</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$27.5</td>
<td>$23.8</td>
<td>$23.8</td>
<td>$100.00</td>
<td>$47.6K</td>
<td>20</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About ConocoPhillips</h3>
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.
Following our analysis of the options activities associated with ConocoPhillips, we pivot to a closer look at the company's own performance.
<h3>ConocoPhillips's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 4,187,539, the COP's price is down by -1.93%, now at $112.55. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>Expert Opinions on ConocoPhillips</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $147.0.
<ul>
<li>An analyst from B of A Securities has revised its rating downward to Buy, adjusting the price target to $147. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ConocoPhillips with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ConocoPhillips's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Viking Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 40%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $67,500, and 8 are calls, for a total amount of $800,845.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $49.0 to $130.0 for Viking Therapeutics over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale activity within a strike price range from $49.0 to $130.0 in the last 30 days. 
<h3>Viking Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720212584_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$70.00</td>
<td>$207.5K</td>
<td>1.6K</td>
<td style="text-align: right;">283</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$7.9</td>
<td>$8.25</td>
<td>$70.00</td>
<td>$206.2K</td>
<td>1.6K</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.3</td>
<td>$14.1</td>
<td>$14.7</td>
<td>$75.00</td>
<td>$147.0K</td>
<td>434</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$0.65</td>
<td>$0.55</td>
<td>$0.65</td>
<td>$65.00</td>
<td>$69.9K</td>
<td>4.6K</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.5</td>
<td>$5.4</td>
<td>$6.5</td>
<td>$130.00</td>
<td>$58.5K</td>
<td>398</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
After a thorough review of the options trading surrounding Viking Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Viking Therapeutics's Current Market Status</h3>
<ul>
<li>With a volume of 1,472,257, the price of VKTX is up 2.64% at $51.8. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 19 days.</li>
</ul>
<h3>Professional Analyst Ratings for Viking Therapeutics</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $105.0.
<ul>
<li>An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $90. </li>
<li>Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Viking Therapeutics, targeting a price of $120. </li>
<li>An analyst from Morgan Stanley has revised its rating downward to Overweight, adjusting the price target to $105. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

VKTX

Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity

The global cryptocurrency markets are trading lower, Friday, amid Mt Gox repayments, Germany transferring Bitcoin and a spike <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39652199/impact-of-mt-gox-germany-sales-on-bitcoin-lettuce-hands-are-flushed-out">in short liquidations.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$56,499</td>
<td>-3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,984.6</td>
<td>-4.9%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$134.7</td>
<td>+0.9%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1041</td>
<td>+-3.2%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001457</td>
<td>-3.9%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data noted Bitcoin reflecting strength in key metrics, with 14.8% growth in large transaction volumes and a 259.7% surge in exchange netflows. Transactions greater than $100,000 also increased in a single day.</li>
<li>Coinglass data pointed to short liquidations at their highest level ($132 million) since May 20. In the past 24 hours, 206,505 traders were liquidated, the total crypto liquidations stood at $582.02 million.</li>
<li>Whale Alert <a href="https://x.com/whale_alert/status/1809296484078174655">data</a> indicated that a dormant address that has 20 BTC, worth $1.1 million, just got activated after 11.1 years.</li>
</ul>
Notable Developments:
<a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39648069/mt-gox-begins-repaying-creditors-after-decade-long-wait">Mt. Gox Begins Repaying Creditors After Decade-Long Wait</a>
<a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39639117/crypto-billionaire-justin-sun-offers-to-buy-bitcoin-off-market-from-german-government-to-m">Crypto Billionaire Justin Sun Offers To Buy Bitcoin Off-Market From German Government To Minimize Price Impact, Lawmaker Slams Authorities For Selling</a>
<a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39638873/bitcoin-bull-mike-novogratz-brings-up-reagan-amid-question-mark-hanging-over-bidens-candid">Bitcoin Bull Mike Novogratz Brings Up Reagan Amid Question Mark Hanging Over Biden&#8217;s Candidacy: &#8216;Power Is A Strange Drug&#8217;</a> <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39639419/amid-bitcoin-crash-peter-schiff-forecasts-prolonged-bear-market-dont-say-i-didnt-warn-you-">Amid Bitcoin Crash, Peter Schiff Forecasts Prolonged Bear Market: &#8216;Don&#8217;t Say I Didn&#8217;t Warn You HODLers&#8217;</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
<h3 class="wp-block-heading">Top Losers:</h3>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Gains +/–</td>
</tr>
<tr>
<td>Core (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">CORE</a>)</td>
<td>$0.8809</td>
<td>-16.5%</td>
</tr>
<tr>
<td>ORDI (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ORDI</a>)</td>
<td>$27.89</td>
<td>-14.3%</td>
</tr>
<tr>
<td>Arbitrum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ARB</a>)</td>
<td>$0.6221</td>
<td>-12.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"> Trader Notes: Fred Krueger in his latest prediction highlighted how the Bitcoin equation could tip into an epic short squeeze. He <a href="https://x.com/dotkrueger/status/1809291475634778373">added</a> "An unknown, but probably massive number of BTC shorts will need to be covered in the next few weeks." Notable crypto trader Flow Horse revealed that he made money by shorting in the last two days as he had a $52,000 target. </figcaption></figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I would be surprised if we moved much lower than this region before a bounce. 52k was my target for this break, and we tagged 53s. Made a lot of money shorting the last 2 days and feel kind of high from it while also having no exposure, sitting at 4% off trading account ATHs.… <a href="https://t.co/lXrdRVW746">pic.twitter.com/lXrdRVW746</a>
&mdash; HORSE (@TheFlowHorse) <a href="https://twitter.com/TheFlowHorse/status/1809261425732334050?ref_src=twsrc%5Etfw">July 5, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cryptoquant founder &amp; CEO Ki Young Ju <a href="https://x.com/ki_young_ju/status/1809293501084909592">says</a> the government-seized Bitcoin being sold is overestimated and suggests not letting this ruin trades.
In another tweet, Young Ju <a href="https://x.com/ki_young_ju/status/1809254974443954403">predicted</a> that the bull cycle will continue early next year. He added, "For those trading in spot, it would be wise to DCA while keeping in mind that it could drop to $47,000 from here."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39649941/bitcoin-down-7-in-7-days-led-by-second-largest-liquidation-event-trader-points-to-demand-w">Bitcoin Down 7% In 7 Days, Led By Second-Largest Liquidation Event: Trader Points To &#8216;Demand Wall&#8217; At </a><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39649941/bitcoin-down-7-in-7-days-led-by-second-largest-liquidation-event-trader-points-to-demand-w">$47,000</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ARB

$BTC

$CORE

$DOGE

$ETH

$JASMY

$ORDI

$SHIB

$SOL

$UNI

Bitcoin, Ethereum, Dogecoin Struggle As Mt Gox Repayments Begin: Crypto Analyst Says BTC 'Could Drop To $47,000 From Here'

The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) CEO Bob Iger rejoined the company in the CEO role in<a href="https://www.benzinga.com/general/entertainment/22/11/29798775/bob-iger-returns-as-disney-ceo-after-reports-of-growing-rift-with-bob-chapek"> November 2022.</a>
In addition to leading Disney, Iger may soon add sports team owner to his list of titles.
What Happened: Disney is<a href="https://www.benzinga.com/sports"> no stranger to sports </a>with its ESPN brand and previous ownership of the Anaheim Mighty Ducks (NHL) and Anaheim Angels (MLB). The company's CEO is nearing a deal to acquire a stake in women's soccer team Angel City, which competes in the National Women's Soccer League (NWSL).
Angel City would be valued at $300 million in the deal, according to a <a href="https://www.semafor.com/article/07/02/2024/disney-ceo-bob-iger-and-willow-bay-to-by-soccer-team">report </a>from Semafor. This would make the team the most valuable women's sports team in the world.
Iger and his wife Willow Bay would buy the controlling stake of Angel City FC according to the report, which would make the duo have a larger stake than <a href="https://www.benzinga.com/news/22/12/29963917/reddit-co-founder-alexis-ohanian-prints-mean-tweets-and-screenshots-how-he-uses-them-as-motivation">current controlling shareholder </a>Reddit co-founder Alexis Ohanian. 
Unlike many other sports teams, there is no majority holder of the team. The unique ownership structure may have led to recent squabbles among owners, with several of them upset over increased spending. The team hired Moelis &amp; Co to seek an investor to assume control of the team's board, as <a href="https://www.latimes.com/sports/soccer/angel-city-fc/story/2024-03-16/angel-city-seeking-new-owner-for-controlling-stake-of-franchise">reported </a>by the Los Angeles Times.
The Bay-Iger group will invest at least $50 million in the team, according to the report. Bay and Iger beat out several interested parties including former Milwaukee Bucks (NBA) owner Marc Lasry and Avie Glazer, who is a member of the Glazer family, who own soccer team Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>), and the NFL's Tampa Bay Buccaneers.
A pitch deck from Bay and Iger shared by Semafor showed the duo highlighting their 25 years of residency in Los Angeles, ability to lead media companies and growth initiatives for the team of expanding international reach and connecting the team to big area events in Los Angeles.
Read Also: <a href="https://www.benzinga.com/m-a/24/07/39605195/going-out-on-top-boston-celtics-for-sale-after-nba-title-large-contracts-handed-to-star-players">Going Out On Top? Boston Celtics For Sale After NBA Title, Large Contracts Handed To Star Players</a>
Why It's Important: Sports teams have consistently achieved record valuations and demonstrated strong performance in recent years.
Angel City counts a handful of celebrities including Natalie Portman, America Ferrera and Eva Longoria as owners along with former soccer players Abby Wambach and Mia Hamm, and other athletes including Serena Williams and Billie Jean King. &nbsp;
Disney is among the media rights partners with the NWSL as part of an overall $240 million three-year <a href="https://www.nwslsoccer.com/news/nwsl-announces-landmark-media-partnerships-with-cbs-sports-espn-prime-video-and-scripps-sports">deal </a>signed in November 2023 by ESPN, Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>). It is currently unclear how Iger's relationship with Disney and the team would impact the rights deal.
A <a href="https://www.sportico.com/feature/nwsl-soccer-team-value-ranking-1234740972/">Sportico </a>ranking of NWSL teams listed Angel City with a $180 million valuation in 2023, double the next highest team San Diego Wave, who were listed at $90 million. The Wave were sold for a then-league record $113 million earlier this year.
Angel City has an estimated $31 million in annual revenue in the Sportico ranking, which is nearly double that of San Diego at $16.3 million.
Sports teams continue to attract interest from billionaires and investors, with Jeff Bezos potentially selling Amazon shares to <a href="https://www.benzinga.com/general/sports/24/07/39621460/jeff-bezos-to-sell-5-billion-in-amazon-shares-could-he-be-raising-cash-for-seattle-seahawks-purcha">buy an NFL team.</a>
NFL star Patrick Mahomes is a <a href="https://www.benzinga.com/general/education/23/02/30870247/5-things-you-might-not-know-about-kansas-city-chiefs-qb-patrick-mahomes">co-owner of NWSL team</a> Kansas City Current.
Investors looking for <a href="https://www.benzinga.com/topic/public-sports-teams">publicly traded stocks</a> with exposure to sports ownership have limited options. A few soccer related options are Manchester United and Juventus (OTC:<a class="ticker" href="https://www.benzinga.com/stock/JVTSF#OTC">JVTSF</a>).
Ares Management Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) <a href="https://www.benzinga.com/news/23/08/33602864/want-to-invest-in-lionel-messis-mls-success-theres-a-new-way-to-get-a-stake-in-inter-miami">is an investor</a> in Inter Miami, the Major League Soccer (MLS) team that landed soccer superstar Lionel Messi last year.
MLS team Toronto FC counts Rogers Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) and BCE Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCE#NYSE">BCE</a>) each as 37.5% team owners.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38260567/bitcoin-soccer-team-adds-winklevoss-twins-as-investors-in-english-premier-league-mission-w">Bitcoin Soccer Team Adds Winklevoss Twins As Investors In English Premier League Mission: Why Shared &#8216;Deep Conviction&#8217; In Bitcoin Is Important</a></li>
</ul>
Photo: Shutterstock

Sports

AMZN

ARES

JVTSF

MANU

PARA

PARAA

Disney CEO Bob Iger Nears Purchase Of Women's Soccer Club, Could Set Record For Priciest Women's Sports Team

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 5 years by 11.92% on an annualized basis producing an average annual return of 25.21%. Currently, DexCom has a market capitalization of $45.21 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 5 years ago, it would be worth $3,122.92 today based on a price of $113.69 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720211416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXCM

Here's How Much You Would Have Made Owning DexCom Stock In The Last 5 Years

Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) has outperformed the market over the past 10 years by 10.43% on an annualized basis producing an average annual return of 21.38%. Currently, Modine Manufacturing has a market capitalization of $5.60 billion. 
Buying $1000 In MOD: If an investor had bought $1000 of MOD stock 10 years ago, it would be worth $6,858.79 today based on a price of $106.95 for MOD at the time of writing.
<h3>Modine Manufacturing's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720211411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Modine Manufacturing 10 Years Ago Would Be Worth This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/MJNE">MJ Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MJNE#OTC">MJNE</a>) shares closed up 36.54% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 22.37% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 11.47% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 11.19% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 6.91% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 6.51% at $0.28</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 4.21% at $1.00</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 3.51% at $11.86</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/KHRNF">Khiron Life Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KHRNF#OTC">KHRNF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/FLWPF">The Flowr</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FLWPF#OTC">FLWPF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 45.18% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 42.22% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Gr</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed down 34.91% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 27.56% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 24.65% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 23.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 13.25% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 9.82% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 9.02% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Props</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 8.48% at $0.60</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 5.86% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 5.60% at $0.12</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 5.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed down 3.88% at $2.23</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 3.65% at $2.11</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 3.36% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.31% at $0.56</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBRRF

CARA

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNGGF

CNTMF

CRON

CVSI

CWBHF

EAST

FLWPF

FUAPF

GBHPF

GRWG

KAYS

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

MGWFF

MJNE

OILFF

RSSFF

SOLCF

TGIFF

YCBD

ZDPY

Bearish Sentiment Across The Cannabis Space - Check Full Movers For July 5, 2024

Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAC#NYSE">PAC</a>, BMV:<a class="ticker" href="https://www.benzinga.com/stock/GAP#BMV">GAP</a>) ("the Company" or "GAP") announces preliminary terminal passenger traffic figures for June 2024, compared with June 2023. &nbsp;
For June 2024, the total number of terminal passengers at GAP's 12 Mexican airports decreased by 2.1%, compared to June 2023. Puerto Vallarta and Guadalajara airports presented an increase in passenger traffic of 0.7% and 0.5%, respectively, while Tijuana and Los Cabos airports presented a decrease in passenger traffic of 5.8% and 0.4% respectively, compared to June 2023. On the other hand, Montego Bay presented a decrease in passenger traffic of 0.2%.

BMV:GAP

Grupo Aeroportuario del Pacifico Reports In June 2024 Passenger Traffic Decreased 1.9% Compared To June 2023

In a bid to support pro-crypto candidates in the upcoming U.S. Senate elections, crypto investment firm Multicoin Capital announced Friday it will match donations made in Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) tokens to the Sentinel Action Fund up to $1 million over the next 10 days.
&#8220;Over the next 10 days, Multicoin Capital will match all SOL donations to Sentinel Action Fund up to $1 million in value,&#8221; Multicoin Capital partner Kyle Samani <a href="https://x.com/KyleSamani/status/1809238868605988959">said.</a>
The Sentinel Action Fund (SAF) is a political action committee (PAC) dedicated to electing pro-crypto candidates to the U.S. Senate.
Under the help of Jessica Anderson, the SAF&#8217;s focus is on backing conservative candidates who advocate for responsible crypto innovation in America.
Multicoin Capital's matching initiative is designed to amplify the impact of contributions. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39650211/decentralized-exchange-pancakeswap-airdrops-367-000-in-zk-tokens">Decentralized Exchange PancakeSwap Airdrops $367,000 In ZK Tokens</a>
This initiative aims to double the impact of each contribution, supporting the Sentinel Action Fund's mission to increase the number of pro-crypto senators like Senator Bill Hagerty (R-TN) .
Highlighting the importance of political engagement, Samani stated, &#8220;We realize that political engagement matters, and it starts with supporting the candidates who believe America needs to remain free for innovation.&#8221; 
He emphasized the need for elected leaders who understand the crypto industry and can advocate for good legislation, policy results, and agency nominees.
Donations can be made through the SAF's website, and the process has been simplified using a new donation tool called Blink, created by SayDialect.
&#8220;Blinks lets you donate directly from X. If you have a Backpack wallet, you can use this Blink today. Support for Phantom wallets should be in the next release,&#8221; explained Samani. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/07/39649054/german-mp-argues-for-retaining-bitcoin-holdings-rather-than-liquidate">German MP Argues For Retaining Bitcoin Holdings Rather Than Liquidate</a></li>
</ul>

Multicoin Capital Announces $1M Match For Pro-Crypto Senate Candidates In Solana Donations

lululemon athletica inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>), a distinguished name in the athleisure and high-performance sportswear world, has often been lauded for its innovative products and strong brand loyalty. However, the stock recently experienced a notable dip in the past month, prompting investors to question whether now is the ideal time to buy.
lululemon&#39;s share price has experienced a downward trend, shedding a notable percentage in the past month. lululemon&#39;s share price has rolled down 7% in the past month, the broader industry has dropped 6.6%, and the Consumer Discretionary sector has declined 0.5%. The stock also traded shy of the S&amp;P 500&#39;s gain of 3.6% in the same period.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c2/70392.jpg?v=664171636" />
Image Source: Zacks Investment Research
At the current price of $300.32, the stock trades closer to its 52-week low of $293.03 reached on May 28, 2024. The current stock price reflects a 42% discount from its 52-week high mark of $516.39.
Furthermore, LULU is trading below its 50 and 200-day moving averages, signaling potential bearish sentiment in maintaining recent performance levels.
<h3>lululemon&#39;s Stock Trades Above 50 and 200-Day Moving Average</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b5/70396.jpg?v=1374675957" />
Image Source: Zacks Investment Research
<h3>Understanding the Recent Decline</h3>
The recent stock decline follows lululemon&#39;s latest Jun 5 earnings report, highlighting slightly lower-than-expected revenue growth and cautious guidance for the upcoming quarters. While generally positive, the company&#39;s recent earnings report gave investors many reasons to mull over, including LULU losing its foothold in the core America market.
Investors noted that LULU&#39;s revenues improved by just 10% in the recent quarter, much below the 24% revenue growth recorded in the year-ago quarter. This marks a notable decline from the company&#39;s double-digit revenue growth trend that the investor community is used to witnessing.
lululemon attributed some of these challenges to inventory shortages in key product lines, such as popular bag designs and essential apparel sizes and colors, particularly in the United States. The company has been working on filling the inventory gaps that resulted in the shortage and expects to replenish inventory in its stores by the second half of fiscal 2024.
Taking a closer look, revenues for lululemon&#39;s Americas business grew 3% in the last reported quarter, displaying a significant slowdown from the growth of 17% in the year-ago quarter. The unfavorable trends in North America due to the inflationary environment have also weighed on the performance of LULU&#39;s competitors, including Columbia Sportswear (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/colm#NASDAQ">COLM</a>) and Ralph Lauren Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rl#NYSE">RL</a>).
Further, lululemon&#39;s business is not shielded from the tough macroeconomic environment, which entails serious pressures on discretionary items spending by consumers. The ongoing rise in inflation and higher interest rates have impacted the income levels of consumers, making them selective about their purchases.
Given the soft trends, the company guided a dim second quarter, with revenue growth of 9-10% year over year.
<h3>Should You Buy lululemon Amid Recent Challenges?</h3>
Although the above discussion might cause some concern, the company holds strong growth potential from an earnings standpoint. Despite the slowed revenues, lululemon has managed to maintain robust gross margin and operating margin levels at 57.7% and 19.6%, respectively, in the first quarter of fiscal 2024.
The company&#39;s improved margins mainly come from its ability to sustain its pricing power in all environments. How does the company achieve this?
lululemon is known for selling high-end apparel, placing it in the premier clothing category. Moreover, the company operates through owned stores and e-commerce portals rather than relying on third-party retailers to generate revenues.
This premium positioning and lack of dependency on third parties give lululemon control over its pricing strategies. Through effective pricing policies, the company efficiently converts revenues into profits.
lululemon&#39;s earnings potential is well reflected by its forward guidance, which predicts the second-quarter fiscal 2024 EPS to be $2.92-$2.97, up from $2.68 in the prior-year quarter. For fiscal 2024, LULU anticipates EPS of $14.27-$14.47, an increase from $12.77 reported in fiscal 2023.
The company is optimistic about its growing presence in the international market, particularly in China, which offers a lucrative opportunity. The company expects the momentum in the international business to continue in fiscal 2024. Over the long term, lululemon expects the international business to represent nearly 50% of its total revenue.
Also, lululemon continues to benefit from progress on its Power of Three X2 growth strategy. As part of the plan, LULU estimates net revenues of $12.5 billion by 2026, implying significant growth from the 2021 reported figure of $6.25 billion.
<h3>Upward Estimate Trajectory</h3>
The Zacks Consensus Estimate for LULU&#39;s fiscal 2024 and 2025 EPS rose 1.4% and 0.5%, respectively, in the last 30 days. The upward revision in earnings estimates indicates analysts&#39; increasing confidence in the stock.
For fiscal 2024, the Zacks Consensus Estimate for LULU&#39;s sales and EPS implies 11.4% and 11.9% year-over-year growth, respectively. The consensus mark for fiscal 2025 sales and earnings indicates 9.9% and 10.1% year-over-year growth, respectively.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/23/70398.jpg?v=751343154" />
Image Source: Zacks Investment Research
<h3>Valuation</h3>
Despite the downside, lululemon is currently trading at a forward 12-month P/E multiple of 20.15X, significantly exceeding the industry average of 12.49X. The stock trades at a premium to its rival NIKE&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) current forward 12-month P/E of 19.08X, which witnessed a significant drop in its market value after its recent earnings release.
The premium valuation indicates that investors have high expectations for lululemon&#39;s future performance and growth potential. However, lululemon&#39;s valuation appears a bit pricey. Investors may be skeptical about buying the stock at these premium levels and may wait for a better entry point.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/3b/70395.jpg?v=712129136" />
Image Source: Zacks Investment Research
<h3>Conclusion</h3>
lululemon&#39;s recent stock decline may appear concerning at first glance, but it could also be seen as an opportunity for savvy investors. Despite the slowdown in revenues and the challenging path ahead, LULU shows resilience and growth potential in its earnings outlook and strategic positioning.
Despite the decline in the stock price, the company&#39;s premium valuation may give some investors pause, suggesting a potentially higher risk profile at current price levels. Therefore, investors should carefully consider their risk tolerance and wait for a more favorable entry point if concerned about current valuations. For those already invested, you should consider holding back the stock for solid long-term prospects.
lululemon currently carries a Zacks Rank #3 (Hold).
<a href="https://www.zacks.com/stock/news/2297193/lululemon-lulu-takes-a-down-road-in-a-month-should-you-buy?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2297193">To read this article on Zacks.com click here.</a>

Earnings

Analyst Ratings

COLM

LULU

Lululemon Takes a Down Road in a Month: Should You Buy?

Management

MVST

On June 28, Microvast Approved Appointment Of Yaser Ali To CFO

These Healthcare stocks are trading higher:-Nexalin Technology Inc (NXL) stock is trading at $2.73, a rise of $0.83, or 56.85%, on high volume.  Nexalin Technology Inc gets a Sentiment Score of Bullish from InvestorsObserver.  -Carmanah Minerals Corp (CARM) stock is trading at $0.06, a rise of $0.01, or 33.33%, on low volu

Healthcare Stocks Moving Up and Down Tuesday: NXL, CARM, QTTB, ACB, VERV, TFFP, CDIO, PTPI

Oppenheimer starts Q32 Bio at outperform, cites lead asset

Homology Medicines GAAP EPS of -$6.33 misses by $4.91

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Q32 Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/qttb-stock-quote/">QTTB</a>) just reported results for the first quarter of 2024.<ul><li>Q32 Bio reported earnings per share of -$6.33. This was below the analyst estimate for EPS of -$2.32.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/qttb-stock-earnings-q32-bio-for-q1-of-2024/">QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024

Q32 Bio Inc (QTTB) has disclosed a new risk, in the Regulation category. Q32 Bio Inc., upon losing its status as a smaller reporting company, faces...

Q32 Bio Inc. Faces New Financial Hurdles as Increased Regulatory Compliance Looms

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of $50.00. ...

Q32 Bio (QTTB) Gets a Buy from Oppenheimer

Q32 Bio (QTTB) has received a new Buy rating, initiated by Leerink Partners analyst, Thomas Smith. Thomas Smith has given his Buy rating due to a c...

Buy Rating Justified by Q32 Bio's Promising Pipeline and Market Potential

Q32 Bio to join Russell 3000 Index

CARM

CDIO

PTPI

TFFP

VERV

Press Releases

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

								Get Alert
QTTB	Q32 Bio Inc. Common Stock	06/26/2024	—	—	44,605	52,721	1	Get Alert
QTTB	Q32 Bio Inc. Common Stock	06/11/2024	—	—	60,110	51,548	1.17	Get Alert
QTTB	Q32 Bio Inc. Common Stock	05/24/2024	—	—	31,663	25,015	1.27	Get Alert
Make more informed trades with Benzinga Pro You're only getting a peek at the whole story!
QTTB	Q32 Bio Inc. Common Stock	05/09/2024	—	—	21,839	31,733	1	Get Alert
QTTB	Q32 Bio Inc. Common Stock	04/24/2024	—	—	13,000	64,295	1	Get Alert
QTTB	Q32 Bio Inc. Common Stock	04/09/2024	—	—	10,272	22,302	1	Get Alert

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Q32 Bio

Short Interest

Q32 Bio (NASDAQ:QTTB) Stock, Short Interest Report

People Also Watch